Susquehanna Fundamental Investments’s CRISPR Therapeutics CRSP Stock Holding History

Susquehanna Fundamental Investments’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$311K	Buy	+5,702	New	+$301K	0.01%	643
2025 Q2	–	Sell	-60,527	Closed	-$2.06M	–	789
2025 Q1	$2.06M	Sell	60,527 -31,860	-34%	-$1.35M	0.03%	522
2024 Q4	$3.64M	Buy	+92,387	New	+$4.36M	0.05%	395
2024 Q2	–	Sell	-23,503	Closed	-$1.6M	–	946
2024 Q1	$1.6M	Buy	+23,503	New	+$1.68M	0.07%	269
2022 Q4	–	Sell	-19,674	Closed	-$1.29M	–	1252
2022 Q3	$1.29M	Buy	+19,674	New	+$1.43M	0.02%	718
2022 Q1	$2M	Buy	31,932 +10,120	+46%	+$635K	0.04%	582
2021 Q4	$1.65M	Buy	21,812 +1,959	+10%	+$171K	0.04%	485
2021 Q3	$2.22M	Sell	19,853 -2,867	-13%	-$360K	0.04%	561
2021 Q2	$3.68M	Buy	+22,720	New	+$2.76M	0.07%	397

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

GSK plc London $602M AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Susquehanna Fundamental Investments's CRSP Position: Q2 2026 in Review

Susquehanna Fundamental Investments opened a new position in CRISPR Therapeutics (CRSP) in Q2 2026: 5,702 shares worth $311K. The stake represents 0.01% of the portfolio and ranks #643 among its holdings. This is a return to the name: Susquehanna Fundamental Investments previously reported a position in CRSP as recently as Q1 2025.

Susquehanna Fundamental Investments first reported a position in CRSP in Q2 2021 and has held it in 9 quarters since. The position peaked at $3.68M in Q2 2021. 524 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

Susquehanna Fundamental Investments held 5,702 shares of CRISPR Therapeutics worth $311K as of Q2 2026.
CRISPR Therapeutics was a new Susquehanna Fundamental Investments position in Q2 2026.
CRISPR Therapeutics made up 0.01% of Susquehanna Fundamental Investments's portfolio in Q2 2026, its #643 holding.
Susquehanna Fundamental Investments first reported a position in CRISPR Therapeutics in Q2 2021 and has held it in 9 quarters since.
Susquehanna Fundamental Investments's CRISPR Therapeutics position peaked at $3.68M in Q2 2021.
524 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Susquehanna Fundamental Investments's 13F filing for Q2 2026, filed 14 Aug 2026.